dr. Wim Terryn
Research Project 1: Micro-inflammatie en atherogenese in uremie en nierfunctievervangende therapie.
Research Project 2: ARCH (PAtient specific image-based computational modeling for impRovement of short- and long-term outCome of vascular access in patients on Hemodialysis therapy)
Research into the effect of creation of a native arterial-venous fistula on vascular and cardiac hemodynamics
Research Project 3: Cochrane-ERA-EDTA project: Collaboration on best practice guidelines.
Guideline-related literature search and evidence grading regarding depression and CKD as well as renal transplantation in collaboration with Cochrane and the European Renal Association - Renal Dialysis and Transplantation Association (ERA-EDTA).
Research Project 4: Belgian screening project for the detection of Anderson-Fabry disease in hypertrophic cardiomyopathy
Screening for Fabry’s disease by means of dried blood spot analysis in men and DNA sequencing in women in 1000 patients with unexplained left ventricular hypertrophy
Research Project 5: School-based screening project to detect the prevalence of alpha galactosidase A mutations in boys (6-12 years) and male young adults (12-18 years)
All male persons between 6 and 18 years and attending a medical school examination in Flanders are elegible. In total 60.000 consecutive males will be included. Informed consent will be asked to the parents of the screenee at the moment the medical school examination is announced. A questionnaire will be handed over to the screenee, consisting of questions directly linked to the signs and symptoms of AFD (appendix A). These questions will reflect major criteria and minor criteria. For a screenee to be proposed the second tier of the screening proces, either one major criterium or three minor criteria must be answered affirmatively.
Research Project 6: Individually adapted immunosuppression in de novo renal transplantation based on immune function monitoring: a prospective randomised study.
Randomised, interventional study in renal transplantation; The main goal is to assess wether farmacodynamic monitoring using the Cylex Immuknow® creates the possibility to select a group of patients that can eventually be treated with an ideal combination of mycophenolic acid and everolimus, a combination that is non-nephrotoxic and gives a better graft function.
Research Project 7: Research project to disclose the impact of posttransplantation hypomagnesemia and to unravel associations with important outcome parameters or surrogates such as diabetes, insulin resistance, kidney function and vascular stifness.
Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation. Van Laecke S, Van Biesen W, Verbeke F, De Bacquer D, Peeters P, Vanholder R. Am J Transplant. 2009 Sep;9(9):2140-9.
Research Project 8: Multicentric study with the following title: ‘Complement activation during hemodialysis in patients with atypical hemolytic uremic syndrome’.
Goal of the study is to find out whether patients with atypical hemolytic uremic syndrome have a greater complement activation during hemodialysis in comparison with patients with an other underlying kidney disease.
Research Techniques and Infastructure
- SphygmoCor® system (AtCor Medical, Sydney, Australia) voor meting van polsgolfsnelheid en polsgolfanalyse via applanatie tonometrie.
- Intravital microscopy (Zeiss)
Liabeuf S, Barreto DV, Barreto FC, Meert N, Glorieux G, Schepers E, Temmar M, Choukroun G, Vanholder R and Massy ZA (2009) Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant.
De Deyn PP, Vanholder R, Eloot S and Glorieux G (2009) Guanidino compounds as uremic (neuro)toxins. Semin Dial 22: 340-345.
Francis Verbeke; Ulrike Haug; Annemieke Dhondt; Werner Beck; Andrea Schnell; Ruth Dietrich; Reinhold Deppisch; Raymond Vanholder (2009) The role of polymer surface degradation and barium sulphate release in the pathogenesis of catheter-related infection. Nephrology Dialysis Transplantation.
Van Laecke S, Van Biesen W, Verbeke F, De Bacquer D, Peeters P, Vanholder R. (2009) Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation. Am J Transplant. 2009 Sep;9(9):2140-9.
A. VAN DER TOL, A. HUSSAIN, M.S. SEVER, S. CLAUS, W. VAN BIESEN, E. HOSTE, S. KHAN, R. VANHOLDER. Impact of local circumstances on outcome of renal casualties in major disasters. Nephrol. Dial. Transplant., 24, 907-912, 2009.
N. LAMEIRE, W. VAN BIESEN, E. HOSTE, R. VANHOLDER. The prevention of acute kidney injury: an in-depth narrative review. Part 2. Nephrol. Dial. Transplant. Plus, 2, 1-10, 2009.
F. LOCATELLI, A. COVIC, K.U. ECKARDT, A. WIECEK, R. VANHOLDER. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol. Dial. Transplant., 24, 348-354, 2009.
C. VON ZUR MUHLEN, E. SCHIFFER, P. ZUERBIG, M. KELLMANN, M. BRASSE, N. MEERT, R.C. VANHOLDER, A.F. DOMINICZAK, Y.C. CHEN, H. MISCHAK, C. BODE, K. PETER. Evaluation of urine proteome pattern analysis for its potential to reflect coronary artery atherosclerosis in symptomatic patients. J. Proteome Res., 8, 335-345, 2009.
E. SCHEPERS, G. GLORIEUX, A. DHONDT, L. LEYBAERT, R. VANHOLDER. Role of symmetric dimethylarginine in vascular damage by increasing ROS via store-operated calcium influx in monocytes. Nephrol. Dial. Transplant., 24, 1429-1435, 2009.
F. LOCATELLI, A. MARTIN-MALO, T. HANNEDOUCHE, A. LOUREIRO, M. PAPADIMITRIOU, V. WIZEMANN, S.H. JACOBSON, S. CZEKALSKI, C. RONCO, R. VANHOLDER. Effect of membrane permeability on survival of hemodialysis patients. J. Am. Soc. Nephrol., 20, 645-654, 2009.
R. VANHOLDER, N. MEERT, W. VAN BIESEN, T. MEYER, T. HOSTETTER, A. DHONDT, S. ELOOT. Why do patients on peritoneal dialysis have low blood levels of protein-bound solutes? Nat. Clin. Pract. Nephrol., 5, 130-131, 2009.
A. COVIC, D. ABRAMOWICZ, A. BRUCHFELD, G. LEROUX-ROELS, D. SAMUEL, W. VAN BIESEN, C. ZOCCALI, R. VANHOLDER. Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) hepatitis C guidelines: a European Renal Best Practice (ERBP) position statement. Nephrol. Dial. Transplant., 24, 719-727, 2009.
S. ELOOT, W. VAN BIESEN, A. DHONDT, R. DE SMET, B. MARESCAU, P.P. DE DEYN, P. VERDONCK, R. VANHOLDER. Impact of increasing haemodialysis frequency versus haemodialysis duration on removal of urea and guanidino compounds: a kinetic analysis. Nephrol. Dial. Transplant., 24, 2225-2232, 2009.
M.S. SEVER, N. LAMEIRE, R. VANHOLDER. Renal disaster relief: from theory to practice. Nephrol. Dial. Transplant., 24, 1730 - 1735, 2009.
A. ARGILES, R. VANHOLDER. Chronic Kidney Disease-related mineral and bone disorders. Nephron. Clin. Pract., 112, C128-C136, 2009.
E. REYNVOET, D.M. VANDIJCK, S.I. BLOT, A.W. DHONDT, J. J. DE WAELE, S. CLAUS, F. M. BUYLE, R. C. VANHOLDER, E.A.J. HOSTE. Epidemiology of infection in critically ill patients with acute renal failure. Crit. Care Med., 37, 2203-2209, 2009.
W. VAN BIESEN, A. PLETINCK, F. VERBEKE, R. VANHOLDER. Acute central hemodynamic effects of peritoneal dialysis. Contrib. Nephrol., 163, 96-101, 2009.
N. LAMEIRE, W. VAN BIESEN, R. VANHOLDER. Dose of dialysis in the intensive care unit: is the venom in the dose or in the clinical experience. Crit. Care, 13, 155-156, 2009.
R. VANHOLDER, D. ABRAMOVICZ, J.B. CANNATA-ANDIA, V. COCCHI, P. COCHAT, A. COVIC, K-U ECKARDT, D. FOUQUE, O. HEIMBURGER, S. JENKINS, A. MACLEOD, E. LINDLEY, F. LOCATELLI, G. LONDON, A. MARTI I MONROS, G. SPASOVSKI, J. TATTERSALL, W. VAN BIESEN, C. WANNER, A. WIECEK, C. ZOCCALI. The future of European Nephrology "Guidelines" – a declaration of intent by European Renal Best Practice. Nephrol. Dial. Transplant Plus, 2, 213-221, 2009.
R. VANHOLDER, F. VERBEKE, W. VAN BIESEN. Vascular access: not enough light at the end of the tunnel? Nat. Rev. Nephrol., 5, 551-552, 2009.
N. MEERT, C. BEERENHOUT, E. SCHEPERS, G. GLORIEUX, J. KOOMAN, R. VANHOLDER. Evolution of protein-bound uraemic solutes during predilution hemofiltration. J. Nephrol., 22, 352-357, 2009.
R. VANHOLDER, S. STUARD, M. BONOMINI, M.S. SEVER. Renal disaster relief in Europe: the experience at l’Aquila, Italy, in april 2009. Nephrol. Dial. Transplant., 24, 3251-3255, 2009.
E. SCHEPERS, G. GLORIEUX, A. DHONDT, L. LEYBAERT, R. VANHOLDER. Flowcytometric calcium flux assay: evaluation of cytoplasmic calcium kinetics in whole blood leukocytes.
S. VAN LAECKE, W. VAN BIESEN, F. VERBEKE, D. DE BACQUER, P. PEETERS, R. VANHOLDER. Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of New-Onset Diabetes after Transplantation. Am. J. Transplant., 9, 2140-2149, 2009.
F.C. BARRETO, D.V. BARRETO, S. LIABEUF, N. MEERT, G. GLORIEUX, M. TEMMAR, G. CHOUKROUN, R. VANHOLDER, Z.A. MASSY. Serum indoxyl sulfate is associated with vascular disease in chronic kidney disease patients. Clin. J. Am. Soc. Nephrol., 4, 1551-1558, 2009.
R. VANHOLDER, Z.A. MASSY. Progress in uremic toxins research: an introduction. Sem. Dial., 22, 321-322, 2009.
R. VANHOLDER, O. ABOU DEIF, A. ARGILES, U. BAURMEISTER, J. BEIGE, P. BROUCKAERT, P. BRUNET, G. COHEN, P.P. DE DEYN, T.B. DRUËKE, D. FLISER, G. GLORIEUX, S. HERGET-ROSENTHAL, W.H. HÖRL, J. JANKOWSKI, A. JÖRRES, Z.A. MASSY, H. MISCHAK, A.F. PERNA, J.M. RODRIGUEZ-PORTILLO, G. SPASOVSKI, B.G. STEGMAYR, P. STENVINKEL, P.J. THORNALLEY, C. WANNER, A. WIECEK. The role of EUTox in uremic toxin research. Sem. Dial., 22, 323-328, 2009.
N. JOURDE-CHICHE, L. DOU, C. CERINI, F. DIGNAT-GEORGE, R. VANHOLDER, P. BRUNET. Protein-bound toxins – update 2009. Sem. Dial., 22, 334-339, 2009.
P.P. DE DEYN, R. VANHOLDER, S. ELOOT, G. GLORIEUX. Guanidino compounds as uremic (neuro)toxins. Sem. Dial., 22, 340-345, 2009.
G. SPASOVSKI, Z. MASSY, R. VANHOLDER. Phosphate metabolism in chronic kidney disease: from pathophysiology to clinical management. Sem. Dial., 22, 357-362, 2009.
K. LUTTROPP, B. LINDHOLM, J.J. CARRERO, G. GLORIEUX, E. SCHEPERS, R. VANHOLDER, M. SCHALLING, P. STENVINKEL, L. NORDFORS. Genetics/genomics in chronic kidney disease - towards personalized medicine? Sem. Dial., 22, 417-422, 2009.
G. GLORIEUX, G. COHEN, J. JANKOWSKI, . Platelet/ leukocyte activation, inflammation, and uremia. Sem. Dial., 22, 423-427, 2009.
R. VANHOLDER, A. ARGILES, J. BEIGE, P. BRUNET, T.B. DRUËKE, D. FLISER, S. HERGET-ROSENTHAL, W.H. HÖRL, A. JÖRRES, A. PERNA, M. RODRIGUEZ-PORTILLO, G. SPASOVSKI, B. STEGMAYR, P. STENVINKEL, C. WANNER, A. WIECEK, Z.A. MASSY. Conservative treatment of the uremic syndrome. Sem. Dial., 22, 449-453, 2009.
W. VAN BIESEN, F. VERBEKE, R. VANHOLDER. We don’t need no education… (Pink Floyd, the Wall). Multidisciplinary predialysis education programmes: pass or fail. Nephrol. Dial. Transplant., 24, 3426-3433, 2009.
R.C. VANHOLDER, W.A. VAN BIESEN, M.S. SEVER. Hurricane Katrina and chronic dialysis patients: better tidings than originally feared? Kidney Int., 76, 687-689, 2009.
W. VAN BIESEN, S. VAN LAECKE, R. VANHOLDER: Treatment of type 2 diabetes in chronic kidney disease: meekly follow the herd or call to arms? Nephrol. Dial. Transplant., 24, 2286- 2287, 2009 (letter).
K. HOLLEVOET, D. BERNARD, F. DE GEETER, N. WALGRAEVE, A. VAN DEN EECKHAUT, R. VANHOLDER, C. VAN DE WIELE, V. STOVE, J.P. VAN MEERBEECK, J.R. DELANGHE: Glomerular filtration rate is a confounder for the measurement of soluble mesothelin in serum. Clin. Chem., 55, 1431- 1433, 2009 (letter).
S. VAN LAECKE, W. VAN BIESEN, F. VERBEKE, D. DE BACQUER, P. PEETERS, R. VANHOLDER. Posttransplant hypomagnesemia as an early predictor of new onset diabetes after transplantation and its relation with calcineurin inhibitors. Am. J. Transplant., 9, 594, 2009.
E. SCHEPERS, G. GLORIEUX, L. LEYBAERT, A. DHONDT, R. VANHOLDER. Symmetric dimethylarginine (SDMA): a pro-inflammatory uremic toxin enhancing cellular calcium influx and activating NF kappa B. Acta Clin. Belg., 64, 174, 2009.
G. LESAFFER, R. DE SMET, A. LOVATO, A. DHONDT, R. VANHOLDER. Influence of teaching by a dietician on the food intake of dialysis patients. Acta Clin. Belg., 64, 173, 2009.
A. PLETINCK, C. CONSOLI, M. VAN LANDSCHOOT, N. TOPLEY, R. VANHOLDER, W. VAN BIESEN. Dietary salt intake reduces peritoneal TGF-beta production and fast transport status in rats. Acta Clin. Belg., 64, 174, 2009.
N. MEERT, S. ELOOT, M.A. WATERLOOS, M. VAN LANDSCHOOT, A. DHONDT, G. GLORIEUX, R. VANHOLDER. Efective removal of uremic solutes by different convective strategies: a prospective cross-over trial. Acta Clin Belg, 64, 174, 2009.
A. PLETINCK, M. VAN LANDSCHOOT, S. STEPPAN, J. PASSLICK-DEETJEN,
R. VANHOLDER, W. VAN BIESEN. Important differences in peritoneal equilibrium
test results. Blood. Purif., 28, 314, 2009.
A. PLETINCK, M. VAN LANDSCHOOT, S. STEPPAN, J. PASSLICK-DEETJEN,
R. VANHOLDER, W. VAN BIESEN. Impact of oral suledoxide in a rat model of
peritoneal perfusion. Blood. Purif., 28, 314, 2009.
E. SCHEPERS, G. GLORIEUX, V. JANKOWSKI, A. DHONDT, J. JANKOWSKI,
R. VANHOLDER. Dinucleoside polyphosphates: newly detected uremic compounds
with an impact on leukocyte oxidative burst. Blood. Purif., 28, 297, 2009.
J. KOOMAN, A. BASCI, F. PIZARELLI, R. VANHOLDER. Dialysate calcium and the European Best Practice Guidelines on hemodynamic instability. Sem. Dial., 22, 311, 2009.
- Eva Schepers (2009): In vitro research for the patho-physiological mechanisms of uremic retention solutes on leukocytes in relation to chronic inflammation and accelerated atherosclerosis in chronic kidney disease.
- Molecular Pathophysiology and Experimental Therapy: (VIB) Prof. P. Brouckaert
- EUTox workgroup
- Vakgroep Civiele Techniek: (UGent) Prof. P. Verdonck en Prof. P. Segers
- Laboratorium voor Scheidingstechnieken: (UGent) Prof P. Sandra
- European Renal Best Practice (ERBP): het sturend orgaan voor nefrologie van de European Renal Association - Renal Dialysis and Transplantation Association (ERA-EDTA).
Clinical Epidemiology: (Public Health, School of Public Health, University of Sydney) Prof. J. Craig
Department of pediatrics: (UZGent) Prof. Linda De Meirleir
Department of medical genetics: (UZGent) Prof. Bruce Poppe
Department of neurology: (UZGent) Dr Dimitri Hemelsoet
O-L-Vrouw Ziekenhuis Aalst